User profiles for Erik P Pioro

Erik P Pioro

Lewis John Pollack Professor of Neurology, Ken & Ruth Davee Dept of Neurology …
Verified email at northwestern.edu
Cited by 10892

Control of microglial neurotoxicity by the fractalkine receptor

AE Cardona, EP Pioro, ME Sasse, V Kostenko… - Nature …, 2006 - nature.com
Microglia, the resident inflammatory cells of the CNS, are the only CNS cells that express the
fractalkine receptor (CX3CR1). Using three different in vivo models, we show that CX3CR1 …

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis

JO Johnson, EP Pioro, A Boehringer, R Chia… - Nature …, 2014 - nature.com
MATR3 is an RNA- and DNA-binding protein that interacts with TDP-43, a disease protein
linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Using exome …

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

…, EJ Kasarskis, EP Pioro… - Annals of Neurology …, 2009 - Wiley Online Library
Objective Amyotrophic lateral sclerosis (ALS) is a devastating, and currently incurable,
neuromuscular disease in which oxidative stress and mitochondrial impairment are contributing …

Dextromethorphan plus ultra Low‐Dose quinidine reduces pseudobulbar affect

EP Pioro, BR Brooks, J Cummings… - Annals of …, 2010 - Wiley Online Library
Objective To evaluate dextromethorphan combined with ultra low‐dose quinidine (DMq) for
treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or …

Defining and diagnosing involuntary emotional expression disorder

…, BR Brooks, RM Herndon, EC Lauterbach, EP Pioro… - CNS …, 2006 - cambridge.org
Uncontrollable episodes of emotional expression occur in a variety of neurological conditions.
This emotional disinhibition syndrome is characterized by episodes of crying or laughing …

Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis

…, P Bettica, BR Brooks, EP Pioro - … Lateral Sclerosis and …, 2020 - Taylor & Francis
Objective To compare the effect of riluzole on median survival in population studies of patients
with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials. Methods: Two …

Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS

…, J Ravits, C Jackson, TM Burns, J Trivedi, EP Pioro… - Neurology, 2020 - AAN Enterprises
Objective To identify preferred neurofilament assays and clinically validate serum neurofilament
light (NfL) and phosphorylated neurofilament heavy (pNfH) as prognostic and potential …

[HTML][HTML] Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis

D Richards, JA Morren, EP Pioro - Journal of the Neurological Sciences, 2020 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative neuromuscular disease
with limited treatment options. The diagnosis of ALS can be challenging for numerous reasons…

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

…, AK Gubitz, C Lomen-Hoerth, CJ McDermott, EP Pioro… - Neurology, 2019 - AAN Enterprises
Objective To revise the 1999 Airlie House consensus guidelines for the design and
implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (…

Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo

EP Pioro, JP Antel, NR Cashman, DL Arnold - Neurology, 1994 - AAN Enterprises
We performed proton magnetic resonance spectroscopic imaging ( 1 H-MRSI) in patients
with motor neuron disease (MND) to evaluate the distribution and extent of cortical neuron …